Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Urgent Transfusion in a New Patient with Rare Blood Type

Catherine Dubé, MD, Scherzinger Kritikopoulos, MLT, Marsha Downie, MLT, Elizabeth Krok, MSc, BSc, ART, MLT, Katerina Pavenski, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-141478

Published: 2020

Journal Articles

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Carolyne Elbaz, MD, Katerina Pavenski, MD, Hina Chaudhry, BSc, Jerome M. Teitel, MD FRCPC, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 1128.

https://doi.org/10.1182/blood-2019-122260

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus

Jeannie Callum, Calvin Yeh, MD PhD, Mark McVey, MD, Andrew Petrosoniak, MD, Stephanie Cope, Troy Thompson, BAHSc, Victoria Chin, Keyvan Karkouti, MD, Avery Nathans, MDMPH PhD, Kimmo Murto, MD, Suzanne Beno, MD, Jacob Pendergrast, MDFRCPC, Andrew McDonald, MDMSc, Neil Adhikari, MDM MSc, Asim Alam, MD, Donald M. Arnold, MD, Lee Barratt, Andrew Beckett, MD, Sue Brenneman, MD, Hina Chaudhry, BSc, Allison Collins, MD, Margaret Harvey, Jacinthe Lampron, MD, Russell MacDonald, MDMPH, Clarita Margarido, MD, Amanda McFarlan, Barto Nascimento, MDMSc, Wendy Owens, Menaka Pai, MSc, MD FRCPC, Sandro Rizoli, MD PhD, Theodora Ruijs, MD, Robert Skeate, PhD, Teresa Skelton, MD, Michelle Sholzberg, MDBSc,FRCPC,MSc, Kelly Syer, Jami-Lynn Viveiros, Josee Theriault, MD, Alan T. Tinmouth, MD FRCPC, Rardi Van Heest, MD, Susan White, Michelle P. Zeller, MD FRCPC, MHPE, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 5792.

https://doi.org/10.1182/blood-2019-121501

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Johanna A. Kremer Hovinga, MD Prof, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD, Ara Metjian, MD

Blood (2018) 132 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2018-99-112177

Published: 2018

Journal Articles

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi, MD PhD, Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 373.

https://doi.org/10.1182/blood-2018-99-112125

Published: 2018

Journal Articles

Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing

Hina Chaudhry, BSc, Michelle Sholzberg, MDM, MSc, FRCPC, Katerina Pavenski, MD

Blood (2018) 132 (Supplement 1): 5051.

https://doi.org/10.1182/blood-2018-99-119399

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Iron Deficiency Project in Pregnancy: Maternal Iron Optimization (IRON MOM)

Jameel Abdulrehman, MD, Grace Tang, MSc, Rosane Nisenbaum, PhD, Jessica Petrucci, MSc, Katerina Pavenski, MD, Andrea Lausman, MD FRCSC, Lisa K. Hicks, MD MSc, Michelle Sholzberg, MDM, MSc, FRCPC

Blood (2018) 132 (Supplement 1): 4893.

https://doi.org/10.1182/blood-2018-99-115371

Published: 2018

Journal Articles

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Paul Knöbl, MD PhD, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2018-99-112174

Published: 2018

Journal Articles

Incidence and Risk Factors for IVIG-Mediated Hemolysis

Jacob Pendergrast, MDFRCPC, Beth Binnington, MSc, Tik Nga Tong, Jeannie Callum, MD, Christine Margaret Cserti-Gazdewich, BSc, MD FRCPC, Wendy Lau, MBBS,FRCPC, Lani Lieberman, MD, Yulia Lin, MD, Katerina Pavenski, MD BSc, FRCPC, Nadine Shehata, MDFRCPC,MSc, Rae Yeung, MD PhD FRCP, Donald R. Branch, PhD

Blood (2017) 130 (Supplement 1): 2398.

https://doi.org/10.1182/blood.V130.Suppl_1.2398.2398

Published: 2017

Journal Articles

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Marie Scully, MD, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD, Ara Metjian, MD, Javier de la Rubia, MD, Katerina Pavenski, MD, Filip Callewaert, PhD, Debjit Biswas, PhD, Hilde De Winter, MD, Robert K. Zeldin, MD

Blood (2017) 130 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-1.LBA-1

Published: 2017

Journal Articles

Utility of Complement and ADAMTS13 Testing in Diagnosis of Thrombotic Microangiopathy: A Single Centre Retrospective Review

Katerina Pavenski, MD FRCP, Christoph Licht, MD, Michael Kirschfink

Blood (2014) 124 (21): 2787.

https://doi.org/10.1182/blood.V124.21.2787.2787

Published: 2014

Journal Articles

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Katerina Pavenski, MD FRCP, Jerome M. Teitel, MD, Gloria Lim, BSc, MSc, MD, Michelle Sholzberg, MD, Michael Kirschfink, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4186.

https://doi.org/10.1182/blood.V124.21.4186.4186

Published: 2014

Journal Articles

HIV-Associated Thrombotic Thrombocytopenic Purpura

Jordana Boro, Katerina Pavenski, MD, FRCP, Kimberley L.S. Ambler, MD, FRCPC, Heather A Leitch, MD, PhD, Lisa K Hicks, MD, MSc, FRCPC

Blood (2011) 118 (21): 4677.

https://doi.org/10.1182/blood.V118.21.4677.4677

Published: 2011

Journal Articles

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

Katerina Pavenski, MD, FRCP, Jordana Boro, John J. Freedman, MD, FRCPC, Marie B. Garvey, MD, Jerome M. Teitel, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC

Blood (2010) 116 (21): 4671.

https://doi.org/10.1182/blood.V116.21.4671.4671

Published: 2010

NARROW

Urgent Transfusion in a New Patient with Rare Blood Type

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Iron Deficiency Project in Pregnancy: Maternal Iron Optimization (IRON MOM)

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Incidence and Risk Factors for IVIG-Mediated Hemolysis

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Utility of Complement and ADAMTS13 Testing in Diagnosis of Thrombotic Microangiopathy: A Single Centre Retrospective Review

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

HIV-Associated Thrombotic Thrombocytopenic Purpura

The Role of ABO Blood Group In TTP Prevalence and Disease Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only